Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0
|
作者：
Coughlan, Anna [1 ]
Klijn, Sven L. [2 ]
Xiao, Hong [3 ]
White, Benjamin [4 ]
Litkiewicz, Michal [5 ]
Kadambi, Ananth [4 ]
Sichevaya, Alina
Hnoosh, Ahmed [6 ]
Miteva, Dimana [7 ]
Yucel, Aylin [3 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Bristol Myers Squibb, Lawrence, NJ USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Evidera, San Francisco, CA USA
[5] Evidera, London, England
[6] Evidera, London, England
[7] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
myelodysplastic syndromes; transfusion independence; burden of illness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-008
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [1] Benefit of Continuing Luspatercept Therapy in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Did Not Achieve Red Blood Cell Transfusion Independence (RBC-TI) by Week 25 in the MEDALIST Study
    Platzbecker, Uwe
    Germing, Ulrich
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zhang, George
    Ha, Xianwei
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 143
  • [2] Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
    Santini, Valeria
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Savona, Michael Robert
    Fenaux, Pierre
    Madanat, Yazan F.
    Oliva, Esther
    Buckstein, Rena
    Jonasova, Anna
    Germing, Ulrich
    Mittelman, Moshe
    Thepot, Sylvain
    Riggs, Jennifer
    Dougherty, Souria
    Berry, Tymara
    Navada, Shyamala
    Xia, Qi
    Sun, Libo
    Zeidan, Amer M.
    Platzbecker, Uwe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S386 - S387
  • [3] Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence ( RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
    Komrokji, Rami S.
    Santini, Valeria
    Fenaux, Pierre
    Savona, Michael R.
    Madanat, Yazan F.
    Berry, Tymara
    Sherman, Laurie
    Navada, Shyamala
    Feller, Faye M.
    Sun, Libo
    Xia, Qi
    Wan, Ying
    Huang, Fei
    Zeidan, Amer M.
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [4] RATIONALE FOR THERAPY DISCONTINUATION IN PATIENTS WITH LOWER-RISK TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES (LR-MDS)
    Gerds, A. T.
    Gupta, S.
    Sekeres, M. A.
    Nazha, A.
    Carraway, H. E.
    Hawthorne, S.
    King-Concialdi, K.
    McGuire, M.
    LEUKEMIA RESEARCH, 2017, 55 : S140 - S141
  • [5] Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions
    Zeidan, Amer M.
    Zhu, Weiwei
    Wang, Rong
    Stahl, Maximilian
    Huntington, Scott F.
    Giri, Smith
    Podoltsev, Nikolai A.
    Gore, Steven D.
    Ma, Xiaomei
    Davidoff, Amy J.
    BLOOD, 2018, 132
  • [6] Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes
    Sangerman, Montserrat Arnan
    Pomares, Helena
    Alonso, Esther
    Grau, Javier
    Galiano, Mercedes
    Encuentra, Maite
    Sureda, Anna
    BLOOD, 2019, 134
  • [7] Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study
    Zeidan, Amer M.
    Garcia-Manero, Guillermo
    DeZern, Amy E.
    Fenaux, Pierre
    Greenberg, Peter L.
    Savona, Michael R.
    Jurcic, Joseph G.
    Verma, Amit
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Laadem, Abderrahmane
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Louis, Chrystal U.
    Linde, Peter G.
    Platzbecker, Uwe
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S319
  • [8] Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    McBride, Ali
    Gajra, Ajeet
    Gentile, Danielle
    Falkenstein, Angelica
    Miller, Talia
    Laney, JaLyna
    Savill, Kristin M.
    Makinde, Adeola Y.
    BLOOD, 2022, 140
  • [9] Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
    Mittelman, Moshe
    Henry, David H.
    Glaspy, John
    Tombak, Anil
    Harrup, Rosemary Anne
    Madry, Krzysztof
    Grabowska, Barbara
    Platzbecker, Uwe
    Lee, Tyson
    Modelska, Katharina
    BLOOD, 2023, 142
  • [10] Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Makinde, Adeola Y.
    Bland, Emily
    Laney, JaLyna
    Garretson, Marne Prime
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345